OR WAIT null SECS
The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.
HJB, a biologics contract development and manufacturing organization (CDMO), announced on Aug. 27, 2020 that it has entered into a strategic partnership for chemistry, manufacturing, and controls (CMC) development and manufacturing with Ansun Biopharma, a clinical-stage biopharmaceutical company, for Ansun’s therapeutic biologics pipeline. The first program in the pipeline is expected to have an investigational new drug (IND) application submitted in 2021.
Under the agreement, Ansun will be able to use HJB’s expertise and capacities, including cell-line development, process and assay development, GMP manufacturing, and IND-enabling services as well as HJB’s expertise in global package, clinical, and commercial supply for the next three years.
“We are very excited about this strategic agreement with HJB, which we consider to be a key piece of foundation for advancing Ansun’s strong biologics pipeline in the coming years,” said George Wang, chief technology officer, Ansun, in a company press release. “As the company continues to expand its pipeline by advancing more early stage assets into clinical development, a partnership with a reliable and capable CDMO such as HJB will accelerate the successful transition of the promising sciences into clinical benefit for global patients.”
“We are proud to be selected as the CMC development and manufacturing partner of Ansun to support expedited and high-quality packages of their innovative biologics programs,” said Jerry Yang, PhD, general manager, HJB, in the press release. “A robust and top-notch supply chain is fundamental to biotech to achieve speed and success to market. The recent global disruption on drug development and manufacturing capacities due to a pandemic has made it even more pressing for companies to secure the much-needed capacities while remaining focused and agile.”
Source: HJB Bio